BioSpace News Archive

BioMidwest

Surgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced a key milestone for its recently introduced posterior fixation platform – the Cortera™ Spinal Fixation System.

December 15, 2022
·
6 min read
Biotech Bay

Thermo Fisher Scientific’s Advanced Analytical Instruments Receive R&D 100 Awards

Thermo Fisher Scientific Inc., the world leader in serving science, received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.

December 15, 2022
·
3 min read
Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024

Pixium Vision SA announces the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in atrophic dry age-related macular degeneration, also known as Geographic Atrophy.

December 15, 2022
·
5 min read
Policy

Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis

The European Commission has expanded the marketing authorization for Dupixent® in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

December 15, 2022
·
17 min read
Policy

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has expanded the marketing authorization for Dupixent® in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

December 15, 2022
·
24 min read
Business

Q2 Interim Report August-October 2022/2023

Biovica International Successful capital acquisition paves the way for launch in the USA

December 15, 2022
·
5 min read
Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)

The diagnostic company SphingoTec GmbH announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT.

December 15, 2022
·
5 min read
Pharm Country

Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market

GenScript USA Inc. recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies.

December 15, 2022
·
4 min read
Drug Development

Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects

Astria Therapeutics, Inc. today announced positive preliminary results from the Phase 1a clinical trial of STAR-0215 in healthy subjects establishing early proof of concept of STAR-0215 as a potential long-acting preventative treatment for HAE. STAR-0215 was well-tolerated at all doses studied.

December 15, 2022
·
8 min read
Drug Development

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaRZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye

Rezolute, Inc. today announced that the Company has initiated a Phase 2 proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of Diabetic Macular Edema (DME).

December 15, 2022
·
7 min read